Alembic Pharmaceuticals Limited (APLLTD)
Outcome of Board Meeting
FY2026 results (audited):
Standalone:
Revenue 665.1bn +20% y-y (554.1bn)
EBITDA 1,569.5bn +20% y-y (1,388.1bn)
EBITDA margin 23.6% (16.3%) +730 bps y-y
PAT 64.0bn +126% y-y (28.3bn)
Consolidated:
Revenue 734.5bn +21% y-y (362.1bn)
EBITDA 1,982.3bn +28% y-y (1,240.2bn)
EBITDA margin 27.0% (16.9%) +1,010 bps y-y
PAT 67.5bn +96% y-y (33.9bn)
Dividend: None stated
Commentary: Exceptional items for FY2026 included Rs. 48.64 crore related to employee benefit obligations and Rs. 18.35 crore write-down on assets of the Sikkim manufacturing facility classified as held for sale.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 APLLTD — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add APLLTD to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Alembic Pharmaceuticals Limited
Important.
The summary above is generated automatically from Alembic Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.